This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be
conducted in the United States. Approximately 210 eligible KRAS wild-type expressing
metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based
chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses
of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or
progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive
either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI
regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and
institutional standard of care).